ETH Zurich and University of Zurich spinout InSphero has now raised $35m and will commercialise its organ-on-a-chip technology.
InSphero, a Switzerland-based drug testing spinout from ETH Zurich and University of Zurich, secured $10m yesterday in a series D round backed by startup studio Venturelab.
The round also featured private investor Jürg Gysi, alongside existing and new, unnamed backers. Gysi, a former general manager of life science product maker Promega’s Switzerland branch, has been president of InSphero’s board of directors since 2014.
InSphero’s preclinical drug testing platform utilises three-dimensional microtissues to build models for liver toxicology, metabolic diseases and…
